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Summary. The Vaccinia-Related Kinases (VRKs)
branched off early from the family of casein kinase (CK)
I and compose a relatively uncharacterized family of the
kinome. The VRKs were discovered due to their close
sequence relation to the vaccinia virus B1R
serine/threonine kinase. They were first described in
phosphorylation of transcription factors that led to the
discovery of an autoregulatory mechanism between
VRK and the tumor suppressor transcription factor p53.
The relevance of VRKs has broadened recently by
introduction of its members as essential regulators in cell
signaling, nuclear envelope dynamics, chromatin
modifications, apoptosis and cellular stress response.
Several phosphorylation substrates have been described,
as well as the first positive and negative regulators of
VRK. We provide an overview of the VRKs across
species and discuss the wide diversity of cellular and
organismal requirements for this kinase family. 
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Introduction
Protein phosphorylation of up to 30% of the
proteome gives eukaryotic protein kinases control over
many cellular processes. Phosphorylation of proteins
generally results in their activation or inhibition, and
may affect their localization and/or stability. The
complement of protein kinases, also known as the
kinome, accounts for up to 2% of protein encoding genes
in eukaryotes and, due to its high conservation during
evolution, provides an excellent super family for
comparative studies across species (Manning et al.,
2002). The human kinome consists of 518 protein
kinases, of which 510 have a murine ortholog
(Caenepeel et al., 2004). Protein kinases can be divided
into 3 groups, based on their enzymatic properties. The
majority of protein kinases transfer a phosphate group
from ATP to the free hydroxyl group of the amino acids
serine or threonine (ser/thr-specific protein kinases),
whilst a smaller group acts on tyrosine (tyr-specific
protein kinases), and a very small number of protein
kinases acts on both (dual specificity kinases). 
Several kinases act in sequential organization of
signal transduction. Mitogen-activated protein kinase
(MAPK) signaling represents the most well
characterized system for signal transmission through
ser/thr kinase complexes assembled on scaffold proteins
that phosphorylate transcription factors (McKay and
Morrison, 2007; Raman et al., 2007). Briefly, MAPK
signaling is initiated by growth factor binding to receptor
tyrosine kinases (RTKs) at the cell membrane
(Sundaram, 2006; McKay and Morrison, 2007). This
triggers RTK dimerization and autophosphorylation
followed by sequential activation of downstream kinases
such as Raf, Mek, and ERK. However, for most kinases,
their substrates and interactions with signal transduction
pathways are not known. In this context a striking
example is represented by GSK3, identified almost forty
years ago for its role in carbohydrate metabolism, and
which is now recognized as an important player in ß-
catenin regulation of epithelial to mesenchymal
transition and cell invasiveness, among other pathways
(Cohen and Frame, 2001).
Because of kinases’ widespread impact on the
activity of the proteome, tight regulation is indispensable
for cellular and organismal homeostasis. Kinases are
regulated by various mechanisms, ranging from the
inhibition/activation at the transcriptional level to protein
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modifications, such as phosphorylation, with many
kinases possessing autophosphorylation ability. Kinases
are counteracted by phosphatases, which enzymatically
remove the phosphate group added by the kinase.
Although a challenging research area due to the
complexity and tight spatial and temporal regulation of
kinases, the elucidating of their function is an important
task for basic cellular and developmental biology, as
well as for translational biomedical research. Probably
one of the most intensively studied kinase regulators is
the small GTPase Ras. The Ras gene was discovered
about 30 years ago as a highly conserved gene, present
in the genome from unicellular yeast to the multiple
copies that can be found in humans (Karnoub and
Weinberg, 2008). Ras is activated by the guanine
nucleotide exchange factor Sos via RTK stimulation. Ras
thereby recruits and activates Raf (McKay and Morrison,
2007). Numerous extracellular stimuli are transduced via
RTK/Ras/MAPK signaling, which explains the crucial
importance of this pathway in cell physiology. An
estimated 20-30% of all human tumors are thought to
contain a mutated Ras gene (Bos, 1989).
In this review we discuss the current state of
research on vaccinia-related kinases (VRKs), more
specifically, their function described so far in mammals,
flies and worms. We discuss the biological impact of this
important protein kinase family and possible future
research prospects. 
The family of vaccinia related kinases
The family of VRKs constitutes a new branch of the
kinome, discovered by homology of its members to the
vaccinia B1R serine/threonine kinase, which is
important for viral replication (Traktman et al., 1989;
Nezu et al., 1997). VRKs have branched off early from
the family of casein kinase (CK) I (Manning et al.,
2002). Three members are known to constitute the
mammalian branch (VRK1, VRK2 and VRK3), whilst
information from invertebrates is presented so far by a
single ortholog in both fruit flies (nucleosomal-histone
kinase-1; NHK-1), and in nematodes (VRK-1). There is
no VRK ortholog known in yeast. Human VRK1
(hVRK1) consists of 396 amino acids and displays 40%
sequence identity with the B1R kinase (Nezu et al.,
1997). hVRK1 contains an N-terminal ser/thr protein
kinase domain and a C-terminal nuclear localization
signal (NLS) (Fig. 1A). Furthermore, its C-terminus
contains an acidic region flanked by 2 basic regions
(basic-acidic-basic (BAB) motif). EST database searches
led to the discovery of a second ser/thr protein kinase
named hVRK2 (Nezu et al., 1997). hVRK2 contains a
transmembrane domain and two overlapping BAB
motifs in its C-terminus (Fig. 1A). hVRK2 was recently
found to have two differentially spliced isoforms, A and
B, which have 508 and 397 amino acids, respectively,
and differ in their C-terminus (Blanco et al., 2006).
hVRK3, which was discovered by further database
searches, consists of 474 amino acids (Nichols and
Traktman, 2004) although skipping of hVRK3 exon 4
may produce a smaller protein of 424 amino acids. The
hVRK3 and mouse mVRK3 enzymes are catalytically
inert due to substitutions in several key residues within
kinase motifs required for catalysis (Nichols and
Traktman, 2004) (Fig. 1A). The murine VRK orthologs
mVRK1-3, including two differentially spliced isoforms
for mVRK1, were described by Zelko and colleagues
(1998). The single Drosophila melanogaster VRK
ortholog NHK-1 was found during biochemical
purification of histone kinases (Aihara et al., 2004). The
nhk-1 gene encodes a 599 amino acid protein with an N-
terminal kinase domain and the characteristic BAB motif
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Fig. 1. The VRKs constitute a conserved protein family. A. All VRKs share a similar serine/threonine protein kinase domain (green) whilst the length of
the extracatalytic domains varies. Human (h) VRK1 and hVRK3 contain a nuclear localization signal (yellow and blue) while hVRK2 has a
transmembrane domain (purple). hVRK1, D. melanogaster NHK-1 and C. elegans VRK-1 contain one or multiple basic-acidic-basic (BAB) motifs (red).
The kinase domain of hVRK3 contains several unusual kinase motifs (crosses) causing it to be catalytically inactive. B. Phylogenetic tree illustrating the
similarity between VRKs of nematodes (Caenorhabditis elegans and C. briggsae), trematodes (Schistosoma mansoni), flies (Drosophila melanogaster
and D. pseudoobscura), sea squirts (Ciona intestinalis), fish (Danio rerio), frogs (Xenopus tropicalis), mice (Mus musculus) and humans (Homo
sapiens). Vertebrate genomes encode three VRK paralogs (VRK1-3) while invertebrates each have a single VRK gene. Modified from
http://www.treefam.org/.
in its C terminus (Aihara et al., 2004) (Fig. 1a).
Caenorhabditis elegans VRK (CeVRK-1) is a 610
amino acid protein, which has an N-terminal kinase
domain and a C-terminal BAB motif (Gorjánácz et al.,
2007). The completion of several genome-sequencing
projects revealed that the increased number of VRK
proteins in mammals presumably reflects the evolution
of the VRK family. Thus, it appears that a single
ancestral VRK gene was duplicated twice when the
vertebrate branch evolved, leaving invertebrates with a
single VRK gene and vertebrates with three VRKs (Fig.
1B).
Protein kinases are grouped into families based
mainly on the structure of their catalytic domains.
Kinase domains can be divided into 12 subdomains, I to
XII, which contain patterns of conserved residues, also
called motifs (Hanks and Hunter, 1995). Most protein
kinases contain an APE motif within subdomain VIII,
but in the CK family, from which the VRK family
branched off, this is usually substituted by a SIN motif.
In VRKs this motif has diverged even further to the
loose consensus (P/S)XD (Nichols and Traktman, 2004).
In both NHK-1 and CeVRK-1 a distinguishing tyrosine
in subdomain VII (DYG) is substituted by a
phenylalanine (DFG). The VRK proteins show high
similarity between phylogenetic orthologs. hVRK1 for
example shows an overall identity of 87% to mVRK1.
hVRK2 and mVRK2 show 68% identity and hVRK3
and mVRK3 show 74% identity. The relatedness
between paralogs is smaller with 44% identity between
hVRK1 and hVRK2, 23% between hVRK2 and hVRK3
and 33% between hVRK1 and hVRK3 (Nichols and
Traktman, 2004) (Fig. 1B). 
hVRK1 and hVRK2 are ubiquitously expressed.
Highest expression of hVRK1 is detected in tissues with
high proliferation rates, such as the fetal liver, testis and
thymus (Nezu et al., 1997). hVRK2 is highly expressed
in fetal liver, skeletal muscles, pancreas, heart,
peripheral blood leukocytes and testis (Nezu et al.,
1997). mVRK1-3 are highly expressed in fetal liver and
the hematopoietic system (blood, thymus and spleen). In
adult murine tissues mVRK1-3 is highly expressed in
liver, kidney and muscle tissues, whilst the
hematopoietic system shows low expression levels (Vega
et al., 2003). Relative expression levels of VRK proteins
in most tissues seem to be correlated with high
proliferation rates. However, the fact that VRK is also
highly abundant in tissues with very low proliferation
rates, such as the adult liver, implies a more complex
regulation of VRK expression. At the subcellular level,
human and murine VRK1 is found within the nucleus,
but is also present in the cytosol in some cell lines
(Nichols and Traktman, 2004; Vega et al., 2004;
Valbuena et al., 2007a). VRK2A localizes to ER
membranes and the nuclear envelope via its C-terminal
transmembrane domain. Despite lacking a recognizable
NLS, VRK2B is detected in both cytoplasm and nucleus
(Nichols and Traktman, 2004; Blanco et al., 2006).
VRK3 contains an N-terminal bipartite NLS and is
localized exclusively to the nucleus (Nichols and
Traktman, 2004). The dynamics of VRK localization
during the cell cycle has so far only been addressed in
flies and worms. In early S phase, Drosophila NHK-1 is
mainly localized in the cytoplasm, but during prophase
the protein changes its localization to condensing
chromatin, where it stays during metaphase to be
excluded from the chromatin at the end of mitosis
(Aihara et al., 2004). CeVRK-1 also shows a highly
dynamic pattern. During interphase, the protein is
nuclear. However, shortly before the cell enters mitosis,
the protein quickly relocates to the nuclear rim until
nuclear envelope breakdown, when it binds to the
chromatin and stays there until the end of mitosis
(Gorjánácz et al., 2007) (Fig. 2A).
Regulation of transcription factors and
tumorigenesis by VRKs
Posttranslational modifications, such as reversible
phosphorylation, acetylation or methylation, play an
important role in regulation of transcription factors. One
of the most studied but complex transcription factors is
p53. p53 is a tumor suppressor protein sometimes called
the ‘gatekeeper of the genome’ due to its important
function in maintaining cellular homeostasis by
regulating cell cycle progression, apoptosis and DNA
replication, in response to a wide variety of cellular
stress signals (Bargonetti and Manfredi, 2002; Vousden
and Lu, 2002). The levels and stability of p53 are
mediated by negative regulators such as Mdm2 (hdm2 in
humans) (Ashcroft and Vousden, 1999), COP1 and Pirh2
(Leng et al., 2003; Dornan et al., 2004) and also protein
stabilization factors such as p300 (Yuan et al., 1999),
MdmX (Stad et al., 2001) and HAUSP (Li et al., 2004).
Interaction with Mdm2 targets p53 for degradation via
the ubiquitin pathway. p53 is regulated by reversible
phosphorylation in many serine or threonine residues in
its N-terminal transactivation domain (Meek, 1999;
Ryan et al., 2001; Toledo and Wahl, 2006). Interestingly,
hVRK1 and hVRK2 phosphorylate p53 in vitro at its
Thr18 residue, located in the transactivation domain
(López-Borges and Lazo, 2000; Barcia et al., 2002; Vega
et al., 2004; Blanco et al., 2006). This prevents the
interaction of p53 with Mdm2 and instead promotes
recruitment of p300 and thereby p53 stabilization (Vega
et al., 2004). p53 and hVRK1 levels are inversely
correlated in cultured cell lines; an increase in p53 levels
results in the downregulation of hVRK1 by a mechanism
that seems to be independent of Mdm2 and is likely not
proteasome-mediated. Instead, an unknown gene targets
hVRK1 to enter the endocytic lysosomal pathway
(Valbuena et al., 2006). The autoregulatory loop between
p53 and VRK1 is a basic cellular control mechanism
under normal growth conditions. When cells are subject
to stress, this balance will shift and result in p53 protein
accumulation and trigger a p53 response (Vega et al.,
2004). However, this autoregulatory loop is non-
functional in a group of lung carcinomas with
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inactivating p53 mutations (Santos et al., 2006; Valbuena
et al., 2007b) and breast carcinomas {P.A.L.,
unpublished results}, resulting in high hVRK1 levels. In
two types of cancer, head and neck squamous cell
carcinomas (HNSCC) and in lung carcinomas, hVRK1
positively correlates with proliferation markers; survivin,
cyclin A, Ki67 and topoisomerase in the case of HNSCC
(Santos et al., 2006) and survivin and cyclin A in lung
carcinomas (Valbuena et al., 2007b). In both cancer
types, VRK1 is inversely correlated with p16. These
case studies of the involvement of VRK1 in different
types of cancers suggest that the role of VRK1 in
transcription factor regulation and cell proliferation is
complex and has multiple molecular faces. p53
transcriptional activity is regulated by transcriptional co-
activators with acetylation function (Roy and
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Fig. 2. Dynamic localization of
VRK-1 and its target BAF-1.
A. Frames from time-lapse
recordings of the first mitotic
division of C. elegans
embryos expressing GFP-
VRK-1 (left column; insert
zoom 3x) and GFP-BAF-1
(middle and right columns).
GFP-VRK-1 accumulates at
the nuclear envelope during
prophase immediately before
nuclear envelope breakdown.
GFP-VRK-1 is chromatin
bound during metaphase
(arrow) and anaphase
(arrows). GFP-BAF-1 is
located at the nuclear
envelope during interphase
and is absent from chromatin
during metaphase. Down-
regulation of VRK-1 by RNAi
(right column) leads to a
strong accumulation of GFP-
BAF-1 on chromatin during
mitosis. Bars: 10 µm. B.
Transmission electron
micrographs of control RNAi
and vrk-1(RNAi) embryonic
nuclei. The nuclear envelope
of the control nucleus is gated
at regular spaces by nuclear
pores (arrowheads). The vrk-
1(RNAi) nuclei show long
stretches of nuclear
membrane almost entirely
without nuclear pores. In
addition, the nuclear size is
severely affected and the
chromatin is highly condensed
and contains intranuclear
membranes (arrows). Bars: 1
µm in top panels; 200 nm in
bottom panel. Reprinted with
permission from (Gorjánácz et
al., 2007).
Tenniswood, 2007). p300 and CBP, which acetylate p53
at two different lysine residues, both inhibit p53-
mediated downregulation of VRK1, but the effect is
independent of their acetyl transferase activity (Valbuena
et al., 2008b). This protective effect of both co-activators
for VRK1 and for the two VRK2 isoforms, VRK2A and
B, is likely a matter of competition for binding to p53,
since the C/H3 binding domain of p300 is needed to
prevent p53-mediated VRK1 degradation (Valbuena et
al., 2008b). VRK2B is thought to be functionally
redundant with VRK1 in adenocarcinoma cell lines, in
which VRK1 appears mainly cytoplasmic. Although
lacking a recognizable NLS, VRK2 enters the nucleus in
cells where VRK1 is cytosolic, indicating a certain
degree of redundancy in the VRK protein family (Blanco
et al., 2006).
In addition to p53, VRK1 has been shown to
phosphorylate transcription factors c-Jun and ATF2
(Sevilla et al., 2004a,b). Triggered by numerous cellular
stress signals, c-Jun is phosphorylated by multiple
MAPKs including ERK and JNK (Chang and Karin,
2001). VRK1 phosphorylates c-Jun in Ser63 and Ser73,
resulting in stabilization and intracellular accumulation
of c-Jun (Sevilla et al., 2004a). Moreover,
phosphorylation of ATF2 Thr73 by VRK1 leads to an
increase in ATF2 transcriptional activity (Sevilla et al.,
2004b). ATF2 functions in cellular responses mediated
by cyclic AMPs, and has been found to form a stable
complex with VRK1 (Sevilla et al., 2004b).
Transcription of ATF2 is induced by multiple kinases
such as JNK, protein kinase A, p38 and VRK1, leading
to a complex regulatory network which might secure
optimal levels of transcriptionally active ATF2 in cells.
The physiological functions of phosphorylation of ATF2
and c-Jun by VRK1 have not been described yet.
Recent data indicate that VRK also regulates cell
cycle progression from G1 to S phase by inducing cyclin
D1 (CCND1) expression (Kang et al., 2008). From late
G1 to early S phase, VRK1 phosphorylates CREB,
thereby stimulating CREB’s binding to the cAMP
response element (CRE) of the CCND1 promoter and
activating transcription. In addition, VRK1 modulates
association of transcription factor ATF2 with the CRE of
CCND1, whereas VRK1 expression is stimulated by
Myc binding to its promoter (Kang et al., 2008).
In a manner dependent on cell stimuli, the concerted
action of kinases generates a complex pattern of
phosphorylation of transcription factors, which are likely
to affect their interactions with other proteins and thus
transcriptional specificity (Fig. 3). This is a likely
explanation for functional differences detected for many
transcription factors whose functions vary depending on
type of stimulation or environment.
Requirement for VRKs in nuclear envelope dynamics 
The nuclear envelope (NE) separates nucleus from
cytoplasm and is composed of an outer (ONM) and an
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Fig 3. Regulation of transcription factors
by VRK1. VRK1 is an important
intracellular kinase for activation and/or
stabil ization of several transcription
factors, such as p53, ATF2, c-Jun and
CREB. These transcription factors are
controlled by a network of protein kinases,
phosphorylating different residues in
response to various extracellular stimuli.
The stimuli to which VRK1 responds are
so far unknown. See text for details and
references.
inner nuclear membrane (INM) gated at regular
distances by nuclear pore complexes (NPCs) allowing
controlled transport between the two compartments. We
have recently identified the sole C. elegans VRK
ortholog, CeVRK-1, as an essential regulator of NPC
formation (Gorjánácz et al., 2007). Downregulation of
CeVRK-1 in C. elegans embryos results in an abnormal
NE containing nuclear membranes but lacking nuclear
pores (Fig. 2B). In C. elegans as well as in vertebrates,
the small chromatin binding protein, barrier-to-
autointegration factor (BAF), is a phosphorylation
substrate for VRK (Nichols et al., 2006; Gorjánácz et al,
2007). In addition, a large-scale yeast two-hybrid study
of Drosophila proteins demonstrated an interaction
between the fly homologs of VRK and BAF (Giot et al.,
2003). Purified, recombinant VRK1 phosphorylates
BAF at its extreme N-terminus on Ser4, and to a lesser
extent and slower rate also on Thr2 or Thr3 (Nichols et
al., 2006). BAF is associated with chromatin in
interphase but is soluble during mitosis (Haraguchi et al.,
2001; Gorjánácz et al., 2007) (Fig. 2A). This dynamic
behavior is critical for BAF’s function in NE assembly
and is regulated by the phosphorylation activity of VRK
(Nichols et al., 2006; Gorjánácz et al, 2007). As
previously mentioned, CeVRK-1 shows a highly
dynamic localization pattern (Fig. 2A), which correlates
with its phosphorylation of BAF at the NE on entry into
mitosis. In the absence of CeVRK-1, BAF is not
released from chromatin during mitosis (Fig. 2A),
causing a failure in NE breakdown and preventing
subsequent postmitotic NE and NPC formation
(Gorjánácz et al., 2007).
Recently it was shown that BAF protects cells
against vaccinia virus infection. Vaccinia virus, like
other poxviruses, replicates its DNA in the cytosol of its
host cell. This requires the expression of the B1 kinase,
which can be detected immediately after infection
(Rempel and Traktman, 1992). At least part of B1’s
function involves phosphorylation of cytosolic BAF
protein to block BAF’s ability to bind the viral genome
and thereby preventing viral DNA replication (Wiebe
and Traktman, 2007). This mechanism thus parallels the
requirement of BAF phosphorylation by VRK1 in NE
dynamics. Moreover, VRK1 can complement the
replication defect of a B1 mutant of vaccinia virus
(Boyle and Traktman, 2004), implying that B1 and
metazoan VRK kinases not only share structural identity
but also functional similarities, albeit in different cell
compartments and situations. 
Involvement of VRK in the stress response 
The cellular stress response involves a wide variety
of different mechanisms to respond to various external
stresses applied to the cell or organism. Interestingly,
recent data have linked the VRK proteins to several
types of cellular stress response. 
The JNK interacting proteins (JIPs) are a family of
scaffold proteins that modulate the MAPKs
(Dhanasekaran et al., 2007). VRK2 interacts with JIP1
and modulates the transcriptional responses triggered by
interleukin-1ß (IL-1ß) (Blanco et al., 2007, 2008) and
hypoxic stress (Blanco et al., 2007). JIP1 assembles a
signalosome that recruits phosphorylated JNK, which in
turn phosphorylates c-Jun and activates AP1
transcription. Both VRK2 isoforms can form a stable
interaction with JIP1, TAK1 and MKK7 and prevent
association of JNK with the complex (Blanco et al.,
2008). Using a kinase-dead VRK2 mutant it was shown
that it is the protein-protein interaction between VRK2
and JIP1, and not the kinase activity of VRK2 that
induces a different conformation of the signalosome
complex, which is unable to interact with JNK (Blanco
et al., 2008). 
VRK2 is also able to protect cells from apoptosis by
interaction with BHRF1, an Epstein-Barr virus gene
product that is homologous to the anti-apoptotic protein
Bcl-2 (Li et al., 2006). VRK2 does not interact with Bcl-
2 and only possesses mild anti-apoptotic activity itself,
but can significantly increase cell survival upon
interaction with BHRF1. This interaction is of interest
for the development of new cancer treatments, such as
targeting epithelial carcinomas that have been linked to
infection with Epstein-Barr virus.
Patterning of chromatin modifications by VRK
Posttranslational modifications at tail domains of
nucleosomal core histones have emerged as important
regulatory mechanism for a multitude of cellular
processes (Berger, 2007). Reversible acetylation,
phosphorylation, ubiquitination and methylation play
essential roles in transcriptional regulation. Histone
modifications affect chromatin dynamics and are thought
to pattern epigenetic codes that control gene expression.
The modifications can both have activating and
inactivating effects and are often present together in
different combinations, denoted as the ‘histone code’
(Berger, 2007). For instance, acetylation of histone H3
and H4 residues generally activates gene expression,
whereas methylation of H3 and H4 can either repress or
induce transcription, depending on the context (Berger,
2007). Phosphorylation of histone H3 Ser10 by multiple
kinases is known to play a role in transcription activation
and chromosome condensation in both mitosis and
meiosis (De Souza et al., 2000; Hsu et al., 2000). In
addition, the phosphorylation of histone H2B by the
Mst1 kinase is induced in apoptotic cells (Chueng et al.,
2003).
Drosophila VRK homolog NHK-1 phosphorylates
the conserved Thr119 of histone H2A (Aihara et al.,
2004; Ivanovska et al., 2005; Ivanovska and Orr-Weaver,
2006) (Fig. 4). Moreover, this phosphorylation event is
required for acetylation of certain lysine residues on
histone H3 and H4 (Ivanovska et al., 2005) (Fig. 4).
NHK-1 is important for formation and maintenance of
the karyosome and metaphase I arrest in meiosis
(Ivanovska et al., 2005; Lancaster et al., 2007) and is
essential for mitotic progression (Cullen et al., 2005).
Mutations in the nhk-1 gene lead to the formation of a
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bipolar metaphase I spindle for each bivalent
chromosome, demonstrating that NHK-1 is required to
hold the chromosomes and the spindle together during
meiosis (Cullen et al., 2005). NHK-1 itself is also
phosphorylated in both mitosis and meiosis (Cullen et
al., 2005) and its activity is controlled by several other
kinases. Aurora B kinase has a positive effect on NHK-1
phosphorylation of histone H2A Thr119 at the
centromeric regions during mitosis whilst cyclin B
degradation reduces centromeric H2A Thr119
phosphorylation at the onset of anaphase (Brittle et al.,
2007). Moreover, in mammals, VRK1 is found to
phosphorylate histone H3 on Thr3 and Ser10 during
mitosis (Kang et al., 2007). Interestingly, both
inactivation of NHK-1 by mutation (Cullen et al., 2005;
Ivanovska et al., 2005) or RNAi against CeVRK-1
(Gorjánácz et al., 2007), as well as overexpression of
mammalian VRK1, leads to hypercondensed chromatin
(Kang et al., 2007). This demonstrates that levels of
VRK activity need to be precisely tuned to maintain
proper chromatin structure.
Implication of VRK in cell signalling pathways
The positive correlation of VRK1 with proliferation
markers such as CDK2, CDK6, and cyclins A and B1
suggested a role for VRK1 in cell cycle progression
(Santos et al., 2006). Indeed, VRK1 has been defined as
an early response gene in cell cycle progression. More
specifically, VRK1 is needed to exit G0 cell cycle phase
and enter G1 phase (Valbuena et al., 2008a). RNAi
downregulation of VRK1 in cultured cells results in a
proliferation block where cells cannot exit G1 phase.
VRK1 is expressed simultaneously with early response
genes myc or fos, and precedes cyclin D1 expression. In
addition, VRK1 protein level is inversely correlated with
p27, an inhibitor of the cell cycle (Valbuena et al.,
2008a). The identification of Myc as an activator of
VRK1 expression is interesting from a therapeutic point
of view, as the Myc signaling pathway is often
upregulated in human cancers (Amati et al., 1998; Kang
et al., 2008). VRK1 could therefore be targeted as a
limiting step in G1/S progression of tumor cells, as
suggested by siRNA knockdown of VRK1 (Vega et al.,
2004; Valbuena et al., 2008a).
The involvement of VRKs in cell cycle progression
is also emerging in C. elegans. The germline in vrk-1
mutants has an apparent cell cycle defect, which results
in the inability to form gametes and thus sterility {E.K.
& P.A.; unpublished results} (Fig. 5A). A second animal
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Fig. 4. NHK-1 and the histone code. A. Histone H2A-T119phos (green) is present in nurse cells (*), follicle cells (arrowhead), and the karyosome
(arrow) in D. melanogaster nhk-1 heterozygous ovaries, and it colocalizes with the DNA (red). Yellow denotes overlap between the signals. A’. The
control karyosome at a higher magnification showing the colocalization of H2A-T119phos with the DNA. B. H2A-T119phos persists in nurse cells (*)
and follicle cells (arrowhead) in the homozygous nhk-1 mutant ovaries. However, the DNA in the mutant oocyte nucleus lacks H2A-T119phos. B’. A
higher magnification showing the absence of H2A-T119phos in the mutant oocyte nucleus. C, E. Histone H3K14 and histone H4K5 are acetylated in
the control karyosomes but not in the nhk-1 homozygous mutant (D, F) (green, H3K14ac (C, D) or H4K5ac (E, F); red, DNA; yellow, overlap between
signals). Reprinted with permission from (Ivanovska et al., 2005).
model system has also generated a preliminary but very
exciting new lead in learning more about the role of
VRK proteins in proliferation; mice carrying a mutation
in the proliferation of germ cells (pog) gene were
compared to mice that have a insertional mutation (gcd)
that knocks down both the pog and the vrk2 gene. Mice
homozygous for the gcd mutation showed a stronger
defect in germ cell proliferation than animals
homozygous for the pog mutant gene alone (Lu and
Bishop, 2003). These results could be interpreted as the
gcd mutation giving a sensitized background for looking
at the pog gene, or it is possible that vrk2 has a function
in germ cell development. In support of this, vrk1
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Fig. 5. Mutation of vrk-1 leads to sterility. Compared to a wildtype C. elegans germline (A), the germline of a vrk-1 mutant at L4 stage (B) contains less
and abnormally enlarged germline cells. Development of a normal vulva (C) (arrowhead) is impaired in vrk-1 mutants, leading to a protruding vulva
phenotype (pvl) (D) (arrowhead). The central vulva precursor cells (E) express GFP under control of the EGL-17 FGF promoter (E’), a downstream
target of the Ras signaling pathway. The EGL-17 promoter is significantly less active in vrk-1 mutants (F, F’).
Table 1. Overview of known VRK phosphorylation substrates.
VRK phosphorylation substrates
Chromatin associated proteins BAF (Thr2/3, Ser4)
Histone H2A (Thr119)
Histone H3 (Thr3, Ser10)
Transcription factors p53 (Thr18)
c-Jun (Ser63, Ser73)
ATF2 (Ser62, Thr73)
JIP1
CREB (Ser133)
These can be classif ied as chromatin associated proteins or
transcription factors. See text for references.
knockdown mice are viable and show no congenital
defects, but become sterile within a few weeks after
birth, suggesting a function for vrk1 in germ cell
proliferation (Dr. Valerie Reinke; personal
communication).
Of the three vertebrate paralogs of the VRK family,
VRK3 is the least characterized to date. mVRK3
interacts with and enhances the activity of vaccinia-H1-
related (VHR) phosphatase, an atypical MAPK
phosphatase (MKP). This results in increased
dephosphorylation of extracellular signal-regulated
kinase (ERK) in the nucleus and thus downregulation of
the ERK signaling pathway (Kang and Kim, 2006,
2008). Since VRK3 proteins are catalytically inactive as
kinases (see above), the regulation of VHR by VRK3
does not involve direct phosphorylation, but rather
suggests a novel mechanism of VRK activity. The ERK
signaling pathway integrates biological responses and
plays a major role in controlling proliferation and
differentiation. Tight regulation of its activity is thus
essential to ensure normal development. With the
discovery of VRK3 as a negative regulator of ERK,
VRK3 may potentially be used to develop new
therapeutic strategies to address deregulation of ERK in
pathologies. 
Proteomic analysis has shown that VRK1 and
VRK2B interact with the Ras-related Ran GTPase
(Sanz-Garcia et al., 2008). Multiple cellular functions for
Ran have been described, such as nucleocytoplasmic
transport, assembly of the mitotic spindle, chromosome
segregation and nuclear envelope formation (Stewart,
2007; Clarke and Zhang, 2008). Binding of RanGDP to
VRK1 inhibits VRK1 autophosphorylation and
phosphorylation of histone H3 Ser10 and Thr3, but the
activity is recovered by interacting with RanGTP (Sanz-
Garcia et al., 2008). The biological function of this novel
interaction is not known, but association of Ran with
VRK1 in the nucleus may be important for VRK1’s role
in transcription factor regulation. The VRK1-Ran
complex also associates with Regulator of Chromosome
Condensation, RCC1, suggesting that VRK1’s effect on
chromatin dynamics may at least in part be mediated via
this complex (Sanz-Garcia et al., 2008). These data
identify Ran, depending on the bound nucleotide, as the
first negative regulator of VRK kinase activity.
As mentioned previously, one of the major cell
signaling pathways is the RTK/Ras/MAPK pathway.
Critical aspects of this pathway have been delineated by
studying vulva development in C. elegans (Sternberg,
2005). Because of its relative simplicity – the C. elegans
vulva consists of 22 cells – organogenesis can be
investigated at single-cell resolution, including cell-cell
communication among vulva cells and between the
vulva and surrounding tissues. Dimerization of the
receptor tyrosine kinase LET-23 (EGFR) triggers its
autophosphorylation followed by binding of adapter
proteins and recruitment of the guanine nucleotide
exchange factor SOS-1. SOS-1 loads the small GTPase
LET-60/Ras with GTP whereby Ras activates the
ERK/MAPK pathway, consisting of the 3 kinases LIN-
45 (Raf), MEK-2 (Mek) and MPK-1 (ERK/MAPK). In
addition to the Ras signaling cascade, other conserved
pathways, such as Wnt or Notch, are involved in vulva
development. Perturbation of the balance between these
pathways causes a variety of phenotypes, ranging from
absence of vulva induction to formation of multiple
vulvae. We have recently discovered that mutation in the
C. elegans vrk-1 gene interferes with the
RTK/Ras/MAPK pathway and results in highly
abnormal vulva morphology (Fig. 5). Determining the
exact position of VRK-1 in this signal transduction
cascade will be highly relevant not only for
understanding how VRK-1 acts in the nematode, but
presumably also to elucidating some of VRK’s many and
interesting functions conserved across species.
Conclusions
Since their initial discovery, the VRKs have gained
significant research interest and have been shown to
function in a wide variety of biological processes. VRK
substrates include various transcription factors, such as
p53 and c-Jun and chromatin proteins BAF and histone
H2A (Table 1). The diversity of substrates correlates
well with VRKs regulating several cellular events, such
as cell cycle progression, apoptosis, chromatin
organization and nuclear envelope disassembly/assembly
cycles. The VRKs have been shown to exert essential
functions both by their phosphorylation abilities as
protein kinases and by direct protein:protein interaction
with different important cellular components. The small
GTPase Ran is the first negative regulator described for
VRK. The identification of Myc as activator of a
putative signaling pathway involved in VRK expression
has made VRK a promising candidate for anti-cancer
research. Much remains to be learnt about this new
emerging kinase family but it is clear that we are gaining
new insights into important biological processes with
exciting long-term therapeutic potentials. 
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